NanoString Technologies Prices Follow-On Offering

| Source: NanoString Technologies, Inc.

SEATTLE, Jan. 23, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced the pricing of its follow-on public offering of $55 million of its common stock at a price to the public of $18.50 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional $8.25 million of its common stock.

The Company intends to use the net proceeds from this offering: (1) to further commercialize its ProsignaTM Breast Cancer Prognostic Gene Signature Assay, including establishing a dedicated oncology sales force; (2) to expand the clinical utility of Prosigna and develop other potential diagnostic product opportunities; (3) to expand life sciences commercial operations to grow and support the installed base of its nCounter® Analysis Systems among life sciences research customers; (4) to develop new life sciences applications, chemistry and instrumentation for its nCounter technology platform; and (5) for working capital and other general corporate purposes. The Company may also use a portion of the net proceeds to acquire, license and invest in complementary products, technologies or businesses; however, it currently has no agreements or commitments to complete any such transaction.

The bookrunning managers of the offering are J. P. Morgan and Morgan Stanley, and the co-managers are Leerink Partners and Robert W. Baird & Co. Incorporated. 

The offering of these securities will be made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014.

A registration statement relating to this offering of common stock has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Investor Contact:
Lynn Pieper of Westwicke Partners
For NanoString Technologies

Media Contact:
Nicole Litchfield
For NanoString Technologies